减少自报青霉素过敏患者氨曲南使用的药师干预效果
在529张床位的社区教学医院,对自报青霉素过敏患者开展回顾性分析,比较药师主导的青霉素过敏评估干预(含药学人员教育与口袋卡开发)实施前后临床应答率。共纳入280例使用革兰阴性覆盖抗生素≥48小时的患者,干预后临床应答率提高(p=0.047),头孢菌素使用增加(p<0.001),氨曲南(p=0.017)和氟喹诺酮类(p=0.008)使用减少,住院时长、院内死亡率及艰难梭菌感染率无显著差异。
要点
- 药师主导的青霉素过敏评估干预可提高自报青霉素过敏患者的临床应答率。
- 干预后头孢菌素使用增加,氨曲南和氟喹诺酮类使用减少。
- 住院时长、院内死亡率和艰难梭菌感染率在干预前后无显著差异。
核心结论
- 实施鼓励自报青霉素过敏患者使用头孢菌素而非氨曲南的干预后,临床应答率和头孢菌素使用率提高,氨曲南和氟喹诺酮类暴露率降低。
研究设计与样本
- 回顾性分析,在529张床位的社区教学医院纳入自报青霉素过敏且接受革兰阴性覆盖抗生素至少48小时的患者,比较药师主导的青霉素过敏评估干预实施前后情况,共280例。
主要发现
- 干预后临床应答率提高(p=0.047)。
- 干预前后抗生素处方类型存在显著差异:头孢菌素使用增加(p<0.001),氨曲南使用减少(p=0.017),氟喹诺酮类使用减少(p=0.008)。
- 中位住院时长(p=0.943)、院内死亡率(p=0.173)和艰难梭菌感染率(p=0.426)在干预前后相似。
临床怎么用
- 临床药师可通过药学人员教育和口袋卡等工具开展青霉素过敏评估,促进自报青霉素过敏患者合理选用头孢菌素、减少氨曲南和氟喹诺酮类使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Evaluation of the clinical impact of a pharmacist led-penicillin allergy assessment initiative to enhance antibiotic selection is reported. METHODS: A retrospective analysis was conducted on patients with a self-reported penicillin allergy (SRPA) at a 529-bed community teaching hospital and compared clinical response rate before and after implementation of a penicillin allergy assessment initiative, consisting of pharmacy staff education and pocket card development. Patients admitted with SRPA who received antibiotics with gram-negative coverage for at least 48 hours were included. The primary outcome was the clinical response rate of penicillin-allergic patients determined preimplementation and postimplementation of the initiative and was based upon improvement in signs and symptoms of infection. Secondary outcomes included antibiotics used, antibiotic durations, length of stay, survival rate, antibiotic discontinuation rate, and Clostridium difficile infection rate. RESULTS: A total of 280 patients were reviewed. Clinical response rate improved after implementation of the initiative (p = 0.047). There were significant differences in the type of antibiotics prescribed between the preimplementation group and the postimplementation group: increased cephalosporin use (p < 0.001), decreased aztreonam use (p = 0.017), and lower fluoroquinolone use (p = 0.008). Median length of stay (p = 0.943), in-hospital mortality rate (p = 0.173), and C. difficile infection rate (p = 0.426) were similar before and after implementation of the initiative. CONCLUSION: After implementation of an initiative to encourage the use of cephalosporins rather than aztreonam in patients with SRPA, the rate of clinical response and cephalosporin use increased and rates of exposure to aztreonam and fluoroquinolones decreased.
引用
- Phan A, Allen B, Epps K, et al. Initiative to reduce aztreonam use in patients with self-reported penicillin allergy: Effects on clinical outcomes and antibiotic prescribing patterns. Am J Health Syst Pharm. 2018. PMID: 30139725. doi:10.2146/ajhp170400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。